Pharmacology
Higher Risk of Venous Thromboembolism with Bevacizumab
Fed Pract. 2009 January;26(1):E2
Patients with cancer who receive bevacizumab may have a higher risk of venous thromboembolism (VTE) than those not receiving the drug, according to a meta-analysis by researchers from Stony Brook University, Stony Brook, NY and Kidney Doctor PLLC, Port Jefferson Station, NY. The antiangiogenic drug is used widely in treating many types of cancer.